uracil has been researched along with Fatty Liver, Nonalcoholic in 14 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with trelagliptin exhibited an improvement in insulin resistance." | 5.62 | The protective effects of trelagliptin on high-fat diet-induced nonalcoholic fatty liver disease in mice. ( Jin, X; Wang, G; Wang, H; Wang, K; Wu, B; Xu, W; Zhang, B; Zhang, L, 2021) |
| "KK‑Ay mice were used to produce an NAFLD model via administration of a choline‑deficient (CD) diet." | 5.48 | Alogliptin alleviates hepatic steatosis in a mouse model of nonalcoholic fatty liver disease by promoting CPT1a expression via Thr172 phosphorylation of AMPKα in the liver. ( Ishihara, S; Ishimura, N; Kinoshita, Y; Mishiro, T; Sato, S; Tobita, H; Yazaki, T, 2018) |
| " 3,5-diiodothyronine (T2) has been used with success in rat models of dyslipidemia and NAFLD, but the outcome of a clinical trial with a synthetic T2 analogue was disappointing." | 5.05 | Thyroid Hormone Analogues: An Update. ( Zucchi, R, 2020) |
| "Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy." | 4.40 | Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023) |
| "Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent, dynamic disease that occurs across the age spectrum and can lead to cirrhosis and hepatocellular carcinoma." | 2.72 | Evolving Role for Pharmacotherapy in NAFLD/NASH. ( Attia, SL; Mouzaki, M; Softic, S, 2021) |
| "Treatment with trelagliptin exhibited an improvement in insulin resistance." | 1.62 | The protective effects of trelagliptin on high-fat diet-induced nonalcoholic fatty liver disease in mice. ( Jin, X; Wang, G; Wang, H; Wang, K; Wu, B; Xu, W; Zhang, B; Zhang, L, 2021) |
| " Treatment with GC-1 upregulated the transcription of CPT1A in the human hepatocyte-derived Huh-7 cell line with a dose-response comparable to that of the native THR ligand, triiodothyronine (T3)." | 1.56 | Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH). ( Beigelman, LN; Blatt, LM; Chanda, S; Deval, J; Gupta, K; Jekle, A; Lin, TI; Luong, XG; McGowan, D; Misner, D; Mukherjee, S; Raboisson, P; Stevens, SK; Stoycheva, A; Symons, JA; Vandyck, K; Williams, C, 2020) |
| "KK‑Ay mice were used to produce an NAFLD model via administration of a choline‑deficient (CD) diet." | 1.48 | Alogliptin alleviates hepatic steatosis in a mouse model of nonalcoholic fatty liver disease by promoting CPT1a expression via Thr172 phosphorylation of AMPKα in the liver. ( Ishihara, S; Ishimura, N; Kinoshita, Y; Mishiro, T; Sato, S; Tobita, H; Yazaki, T, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 10 (71.43) | 2.80 |
| Authors | Studies |
|---|---|
| Caddeo, A | 1 |
| Kowalik, MA | 1 |
| Serra, M | 1 |
| Runfola, M | 1 |
| Bacci, A | 1 |
| Rapposelli, S | 1 |
| Columbano, A | 1 |
| Perra, A | 1 |
| Harrison, SA | 2 |
| Bashir, MR | 1 |
| Guy, CD | 1 |
| Zhou, R | 1 |
| Moylan, CA | 1 |
| Frias, JP | 1 |
| Alkhouri, N | 2 |
| Bansal, MB | 1 |
| Baum, S | 1 |
| Neuschwander-Tetri, BA | 1 |
| Taub, R | 1 |
| Moussa, SE | 1 |
| Ratziu, V | 1 |
| Guaraldi, G | 1 |
| Maurice, JB | 1 |
| Marzolini, C | 1 |
| Monteith, K | 1 |
| Milic, J | 1 |
| Tsochatzis, E | 1 |
| Bhagani, S | 1 |
| Morse, CG | 1 |
| Price, JC | 1 |
| Ingiliz, P | 1 |
| Lemoine, M | 1 |
| Sebastiani, G | 1 |
| Zucchi, R | 1 |
| Sinha, RA | 1 |
| Bruinstroop, E | 1 |
| Singh, BK | 1 |
| Yen, PM | 1 |
| Attia, SL | 1 |
| Softic, S | 1 |
| Mouzaki, M | 1 |
| Luong, XG | 1 |
| Stevens, SK | 1 |
| Jekle, A | 1 |
| Lin, TI | 1 |
| Gupta, K | 1 |
| Misner, D | 1 |
| Chanda, S | 1 |
| Mukherjee, S | 1 |
| Williams, C | 1 |
| Stoycheva, A | 1 |
| Blatt, LM | 1 |
| Beigelman, LN | 1 |
| Symons, JA | 1 |
| Raboisson, P | 1 |
| McGowan, D | 1 |
| Vandyck, K | 1 |
| Deval, J | 1 |
| Wang, G | 1 |
| Wu, B | 1 |
| Zhang, L | 1 |
| Jin, X | 1 |
| Wang, K | 1 |
| Xu, W | 1 |
| Zhang, B | 1 |
| Wang, H | 1 |
| Younossi, ZM | 1 |
| Stepanova, M | 1 |
| Taub, RA | 1 |
| Barbone, JM | 1 |
| Amano, Y | 1 |
| Tsuchiya, S | 1 |
| Imai, M | 1 |
| Tohyama, K | 1 |
| Matsukawa, J | 1 |
| Isono, O | 1 |
| Yasuno, H | 1 |
| Enya, K | 1 |
| Koumura, E | 1 |
| Nagabukuro, H | 1 |
| Tobita, H | 1 |
| Sato, S | 1 |
| Yazaki, T | 1 |
| Mishiro, T | 1 |
| Ishimura, N | 1 |
| Ishihara, S | 1 |
| Kinoshita, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection[NCT04369807] | 693 participants (Actual) | Observational | 2020-04-21 | Completed | |||
| A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-controlled Study of MGL-3196 in Patients With Non-alcoholic Steatohepatitis[NCT02912260] | Phase 2 | 125 participants (Actual) | Interventional | 2016-09-30 | Active, not recruiting | ||
| A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food-effect of Single and Multiple Oral Doses of RJ4287 in Healthy Volunteers[NCT05921006] | Phase 1 | 98 participants (Anticipated) | Interventional | 2023-06-13 | Recruiting | ||
| Improvement of Laboratory Diagnostics in Hypothyroid Patients Using Levothyroxine[NCT06083636] | 500 participants (Anticipated) | Observational | 2022-07-26 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for uracil and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Thyroid Hormone Analogues: An Update.
Topics: Acetates; Anilides; Animals; Central Nervous System Diseases; Clinical Trials as Topic; Diiodothyron | 2020 |
Evolving Role for Pharmacotherapy in NAFLD/NASH.
Topics: Adult; Benzhydryl Compounds; Chenodeoxycholic Acid; Child; Clinical Trials, Phase III as Topic; Fibr | 2021 |
3 trials available for uracil and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life.
Topics: Adult; Double-Blind Method; Female; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic | 2022 |
9 other studies available for uracil and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
TG68, a Novel Thyroid Hormone Receptor-β Agonist for the Treatment of NAFLD.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression R | 2021 |
Improving NASH with a little help from thyromimetics.
Topics: Double-Blind Method; Humans; Non-alcoholic Fatty Liver Disease; Pyridazines; Thyroid Hormones; Uraci | 2019 |
Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196).
Topics: Drug Development; Humans; Non-alcoholic Fatty Liver Disease; Pyridazines; Thyroid Hormone Receptors | 2020 |
New Drugs for NASH and HIV Infection: Great Expectations for a Great Need.
Topics: Anti-Retroviral Agents; Chalcones; Chenodeoxycholic Acid; Cholic Acids; Clinical Trials, Phase III a | 2020 |
Thyroid Hormones and Thyromimetics: A New Approach to Nonalcoholic Steatohepatitis?
Topics: Double-Blind Method; Humans; Non-alcoholic Fatty Liver Disease; Pyridazines; Thyroid Hormones; Uraci | 2020 |
Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH).
Topics: Acetates; Angiopoietin-Like Protein 4; Animals; Cell Line, Tumor; Cholesterol, LDL; Diet, High-Fat; | 2020 |
The protective effects of trelagliptin on high-fat diet-induced nonalcoholic fatty liver disease in mice.
Topics: Animals; Diet, High-Fat; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Ura | 2021 |
Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis.
Topics: Animals; Dose-Response Relationship, Drug; Drug Combinations; Hypoglycemic Agents; Liver; Liver Cirr | 2018 |
Alogliptin alleviates hepatic steatosis in a mouse model of nonalcoholic fatty liver disease by promoting CPT1a expression via Thr172 phosphorylation of AMPKα in the liver.
Topics: AMP-Activated Protein Kinases; Animals; Carnitine O-Palmitoyltransferase; Disease Models, Animal; Ge | 2018 |